Abstract | The transcriptional and metabolic programmes that control CD8 + T cells are regulated by a diverse network of serine/threonine kinases. The view has been that the kinases AKT and mammalian target of rapamycin (mTOR) control T cell metabolism. Here, we challenge this paradigm and discuss an alternative role for these kinases in CD8 + T cells, namely to control cell migration. Another emerging concept is that AMP-activated protein kinase (AMPK) family members control T cell metabolism and determine the effector versus memory fate of CD8 + T cells. We speculate that one link between metabolism and immunological memory is provided by kinases that originally evolved to control T cell metabolism and have subsequently acquired the ability to control the expression of key transcription factors that regulate CD8 + T cell effector function and migratory capacity. 
Cytotoxic T cells that express the CD8 co-receptor and recognize peptide-MHC class I complexes have a key role in clearing viral infections. During a primary immune response to viruses, naive CD8 + T cells expressing pathogen-specific T cell receptors (TCRs) clonally expand and differentiate into effector CD8 + T cells that control the primary infection. This differentiation process produces effector cytotoxic T lymphocytes (CTLs) that can destroy virally infected cells through the targeted secretion of perforin and granzymes from lytic granules. After the primary infection is cleared there is a contraction phase when most of the effector CTLs die by apoptosis. However, an effective immune response also produces a stable population of antigen-specific longlived memory CD8 + T cells that can respond rapidly to clear secondary infections [1] [2] [3] . The transcriptional programmes that determine whether naive T cells differentiate into effector cells or memory cells are controlled by antigen receptors, co-receptors, cytokines and chemokines. These molecules also coordinate T cell metabolism and ensure that during an immune response T cells increase their uptake of glucose, amino acids and iron, and switch to using aerobic glycolysis to generate ATP. These changes increase cellular nutrient uptake and energy production to meet the biosynthetic demands of effector T cell functions. Another important consideration is that activation of CD8 + T cells induces essential changes in their migratory patterns to redirect effector CTLs to sites of inflammation and concomitantly reduce their capacity to home to secondary lymphoid tissues. The challenge is thus to understand the molecular pathways that synchronize metabolism and migration with effector and memory T cell differentiation.
In this Opinion article, we explore how serine/threonine kinases, including AKT (used to refer to all three isoforms; also known as PKB) and members of the AMPactivated protein kinase (AMPK) family (such as LKB1 (also known as STK11) and AMPK), coordinate these processes. We challenge the dogma that AKT has an obligatory role in controlling T cell metabolism and survival, and discuss how LKB1 is perhaps more important. We then discuss the concept that the physiological role for AKT is to coordinate the repertoire of adhesion molecules and chemokine receptors that are expressed by CD8 + T cells, and hence regulate their trafficking and migration.
We also discuss the emerging idea that changes in T cell metabolism dictate whether naive CD8
+ T cells become memory T cells or terminally differentiated effector T cells. Finally, we consider whether there really is any evidence for such a link or whether the link between metabolism and immunological memory reflects that kinases that evolved to control cell metabolism have acquired the ability to control T cell migration. The regulation of T cell migration by such kinases could then influence the fate of CD8 + T cells in terms of the decision to produce memory versus terminally differentiated effector CD8 + T cells.
Metabolism and CTLs
It was recognized over 30 years ago that it is important for CTLs to control their cellular metabolism and to coordinate glycolysis and oxidative phosphorylation [4] [5] [6] . Quiescent naive and memory CD8 + T cells only require energy to prevent cell atrophy and for survival and migration. By contrast, effector CTLs have higher energy demands because they need to proliferate rapidly and produce effector cytokines. It is thus essential that CD8 + T cells can increase cellular energy production and nutrient uptake to satisfy increased biosynthetic demands as and when they occur 7 . One mechanism involves the upregulation of amino acid transporters, the transferrin receptor and glucose transporters at the cell surface in response to extrinsic signals from antigens and cytokines [8] [9] [10] . This ensures that nutrient uptake is increased to meet the metabolic and biosynthetic needs of the T cell as it responds to either developmental or pathogenic cues.
One particularly important metabolic change that occurs in activated T cells is the switch from oxidative phosphorylation to aerobic glycolysis; that is, the cells use an oxygen-independent mechanism to produce ATP from glucose 12 . Effector CTLs may have to migrate, survive and produce effector cytokines in the hypoxic environment at sites of inflammation. Moreover, lymphoid tissue is also relatively hypoxic as the oxygen tension ranges from 1 to 5% 13 . A switch to aerobic glycolysis may thus help CTLs to proliferate and mediate their effector function in relatively hypoxic conditions. However, the problem Nature Reviews | Immunology
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PH domain PtdIns(3,4,5)P 3 PtdIns(4,5)P 2 PDK1 mTORC2 P AKT P with glycolysis is that it is a relatively inefficient route to produce ATP as it only yields two molecules of ATP for every molecule of glucose. This is in contrast to oxidative phosphorylation, which can produce at least 30 molecules of ATP from each molecule of glucose. Therefore, cells must be able to sustain high levels of glucose uptake to derive energy solely through glycolysis. In CTLs the key process to ensure sustained high-level glucose uptake is the upregulation of the expression and function of glucose transporter type 1 (GLuT1; also known as SLC2A1) 8 . It is also essential that T cells increase the activity or the expression of rate-limiting glycolytic enzymes, such as hexokinase 1, hexokinase 2 and phosphofructokinase 1 (Refs 12, 14) . The dependence of CTLs on aerobic glycolysis makes these cells dependent on exogenous glucose 7, 15 . nevertheless, the advantage of glycolysis, and hence the most probable reason that the glycolytic switch occurs in CTLs, is that glycolysis promotes the use of glucose as a source of carbon for the synthesis of nucleic acids and phospholipids 12 . An increase in the production of such biosynthetic precursors would be favourable for CTLs, which have to maintain high levels of protein and lipid synthesis for their effector functions.
AKT and T cell metabolism: the dogma. How do T cells increase their metabolism in response to immune stimulation? The current dogma is that the serine/ threonine kinase AKT has a key role. This kinase is rapidly activated in response to TCR triggering or cytokines such as interleukin-2 (IL-2) and IL-15 . The activation of AKT in T cells is regulated by stimuli that increase the levels of phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P 3 ), which is generated by direct phosphorylation of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P 2 ) by phosphoinositide 3-kinase (PI3K). AKT activation also requires its phosphorylation on Thr308 by 3-phosphoinositidedependent protein kinase 1 (PDK1) 18, 19 and on Ser473 by mammalian target of rapamycin (mTOR) complex 2 (mTORC2) 20, 21 PDK1 and AKT both have a pleckstrin homology (PH) domain that binds PtdIns(3,4,5)P 3 with high affinity. The interaction between PtdIns(3,4,5)P 3 and AKT is required for PDK1 to phosphorylate AKT on Thr308. However, the binding of PtdIns(3,4,5)P 3 to PDK1 is not essential for the catalytic activity of PDK1, although it does promote localization of the enzyme to the plasma membrane and support efficient induction of high levels of AKT activity 18, 22 . The model that AKT controls metabolic and survival programmes in T cells stems from experiments showing that PI3K inhibitors, which block AKT activation, prevent increases in both glucose and amino acid uptake by activated T cells 16, 23 . In addition, constitutively active mutants of AKT can promote glucose uptake by controlling the expression of GLuT1 (Ref. 24) . The mechanism for AKT control of glucose transporter expression is not fully understood, but AKT substrates include the RAB GTPase-activating proteins AS160 (AKT substrate of 160 kDa; also known as TBC1D4) and TBC1D1, which can control the translocation of glucose transporters to the cell membrane [25] [26] [27] . Further evidence that PtdIns(3,4,5)P 3 -PDK1-mediated activation of AKT controls T cell metabolism was obtained from studies of T cell progenitors in the thymus. In these cells, AKT stimulation is essential for the increases in glucose uptake and in the expression of amino acid transporters and the transferrin receptor that are required to support the survival and proliferation of these cells during thymopoiesis 9, 28 . T cell progenitors that do not express PDK1 or AKT thus fail to express these important nutrient receptors and do not survive, as they cannot meet the metabolic demands of thymopoiesis.
AKT and T cell metabolism: the reality. The consensus view of AKT is that it has a universal role in controlling T cell metabolism. It is thus assumed that the metabolic role for AKT in T cell progenitors is recapitulated in all peripheral T cells. Indeed, many of the extrinsic stimuli that control peripheral T cell metabolism activate PI3K and AKT 17, 29, 30 . There are also numerous experiments that have used PI3K inhibitors in different T cell populations and support the idea that PI3K, and hence AKT, are important for glucose uptake and/or protein synthesis 23, 31, 32 . However, a criticism of many of these studies is that one of the most commonly used PI3K inhibitors (Ly294002) has off-target effects and can inhibit mTOR and the PIM family of serine/threonine kinases 33, 34 . A second criticism is that there is frequently an assumption that all PI3K-dependent responses are mediated by AKT and very little consideration is given to the role of other downstream effector molecules of PtdIns(3,4,5)P 3 , such as TEC family tyrosine kinases and guanine nucleotide exchange factors for RHO GTPases 35 . In this context, evidence for AKTindependent pathways that control T cell metabolism, survival and proliferation have now been documented. Although constitutively active AKT has been shown to stimulate glucose uptake and to promote cell growth and survival 36 , it differentially controls T cell subsets, promoting the survival of CD4
+ but not CD8 + T cells 37 . Another example of how T cell metabolism and survival can be independent of AKT comes from in vivo studies of the role of PDK1. For example, deletion of PDK1 does not prevent IL-7 from supporting CD4 + T cell survival 38 . One other in vivo demonstration of the AKT independence of T cell metabolism comes from studies of the role of PDK1 in the pathology caused by deletion of the tumour suppressor PTEn (phosphatase and tensin homologue) 19 . This protein is a lipid phosphatase that removes the phosphate at the D3 position of the inositol ring of PtdIns(3,4,5)P 3 . The tissue-specific deletion of PTEn in thymic T cell progenitors increases cellular levels of PtdIns(3,4,5)P 3 and is sufficient to strongly activate PDK1-AKT signalling. PTEn deletion also causes T cell lymphomagenesis, which results in the development of lymphoma cells -large blastoid cells indicative of unrestrained activation of metabolic pathways 39 . In normal T cell progenitors, PDK1-AKT signalling controls nutrient receptor expression and cell metabolism and When there are low levels of phosphatidylinositol-3,4,5-trisphosphate (Ptdins(3,4,5)P 3 ) in the plasma membrane, AKT is in an inactive conformation and cannot be phosphorylated by the upstream activating kinase 3-phosphoinositidedependent protein kinase 1 (PDK1) (not shown). When Ptdins(3,4,5)P 3 levels increase in the plasma membrane -for example, following the activation of phosphoinositide 3-kinase (Pi3K), which phosphorylates phosphatidylinositol-4,5-bisphosphate (Ptdins(4,5)P 2 ) -AKT binds Ptdins(3,4,5)P 3 through its pleckstrin homology (PH) domain. Binding of Ptdins(3,4,5)P 3 to the PH domain of AKT induces a conformational change within its kinase domain allowing PDK1 to phosphorylate the critical residue required for AKT kinase activity, Thr308. Mammalian target of rapamycin complex 2 (mTORC2) also phosphorylates AKT at the carboxy-terminal ser473 site to fully activate its kinase activity. PDK1 has a PH domain that can bind Ptdins(3,4,5)P 3 but this interaction is not essential for PDK1 catalytic activity.
hence is essential for the proliferation and survival of these cells 9 . However, deletion of PTEn bypasses the normal PDK1-AKTcontrolled metabolic checkpoint in T cell progenitors, such that the growth and proliferation (but not malignant transformation) of PTEn-deficient T cells can occur independently of PDK1 and AKT signalling 19 . This result is surprising because it was assumed that the requirement for PDK1 in the malignant transformation of PTEn-deficient thymocytes was due to its control of cell metabolism through the activation of AKT. The fact that the metabolism, survival and proliferation of PTEn-deficient thymocytes can be independent of PDK1 and AKT exemplifies how AKT does not have an equal and obligate role in controlling metabolism in all T cell populations.
AKT-independent mechanisms. What are the candidates that may mediate AKTindependent control of T cell metabolism? One possibility is other members of the AGC family of serine/threonine kinases, such as 90 kDa ribosomal protein S6 kinase (p90-RSK), 70 kDa ribosomal protein S6 kinase 1 (p70-S6K1) or serum/glucocorticoidregulated kinase (SGK), which share substrate specificity with AKT [40] [41] [42] . Other candidates are the PIM family of serine/ threonine kinases because they have been shown to have a role in T cell survival, and they also have a substrate specificity similar to AKT 43 . Moreover, the PIM kinases are inhibited by the PI3K inhibitor Ly294002 (Ref. 34) . Other proteins that are emerging as possible controllers of T cell metabolism include the mitogen-activated protein kinases (MAPKs) extracellular signalregulated kinase 1 (ERK1) and ERK2, which have recently been described as essential for the induction of glutamine uptake that accompanies T cell activation 44 . It has also been proposed that the serine/threonine kinase LKB1 is important for T cell metabolism. LKB1 is an evolutionarily conserved kinase that can regulate cellular responses to energy stress in many cell types and is required to synchronize cellular energy checkpoints and cell division in Drosophila melanogaster 45 . LKB1 phosphorylates and activates multiple AMPK family members including AMPK 46, 47 . In T cells, LKB1 phosphorylates and activates AMPK in response to increases in cellular AMP/ATP ratios, but AMPK can also be activated through a Ca 2+ -calmodulin-dependent protein kinase pathway in response to TCR triggering 48 .
In many cell lineages, AMPK acts to restore cellular energy balance by inhibiting ATPconsuming processes and stimulating ATP-generating pathways 49 . It has thus been proposed that in T cells, increases in intracellular Ca 2+ concentrations that activate calmodulin-dependent kinases stimulate AMPK to promote the conservation and accelerated production of ATP in anticipation of energy supplies becoming depleted by T cell activation.
What is the evidence that LKB1 and AMPK contribute to the regulation of the energy status of T cells? One compelling set of data shows that LKB1 is essential for the survival and development of thymic T cell progenitors that have undergone TCR β-selection and is also required for the survival and proliferation of peripheral CD8 + T cells 50, 51 . Importantly, LKB1 seems to be necessary for several key metabolic processes in T cells. For example, LKB1 controls the expression of CD98 (also known as 4F2hc), a key subunit of L-system amino acid transporter 1, and is also required to sustain the phosphorylation of the ribosomal S6 subunit, a crucial regulator of protein synthesis 51 . Interestingly, LKB1 is an essential regulator of AMPK in energystressed T cells 50 , yet the loss of AMPK does not phenocopy the loss of LKB1. AMPKdeficient T cells have increased sensitivity to energy stress in vitro but can still develop normally in the thymus in vivo in contrast with LKB1-deficient T cells 51, 52 . This is most likely due to redundancy in vivo between different AMPK family members for the control of T cell metabolism; the loss of LKB1 expression would circumvent this redundancy by preventing the activation of multiple AMPK family members.
Therefore, contrary to the current dogma, AKT does not have an obligatory role in controlling T cell metabolism, and evidence is emerging that LKB1-regulated kinases do have a role. 
Aerobic glycolysis
Glycolysis is an anaerobic metabolic pathway that converts glucose to pyruvate, which can then be either further metabolized in the presence of oxygen to generate ATP through oxidative phosphorylation, or converted to lactate. The term 'aerobic glycolysis' describes the conversion of glucose to lactate even though oxygen is present and thus not a limiting factor. for example, most cancer cells predominantly produce energy by a high rate of glycolysis followed by lactic acid fermentation in the cytoplasm, whereas most normal cells use a comparatively low rate of glycolysis followed by oxidation of pyruvate in mitochondria (termed the Warburg effect).
β-selection
A process involving a cell autonomous signalling cascade that leads to the proliferation and survival of thymocytes that have undergone successful recombination at the locus that encodes the β-chain of the T cell receptor (TCR) to express a functional pre-TCR on their cell surface.
Granzymes secreted serine proteases that enter target cells through perforin pores, where they then cleave and activate intracellular caspases to initiate target-cell apoptosis.
L-system amino acid transporter 1
A heterodimeric membrane transport protein that preferentially transports neutral branched amino acids (such as valine, leucine and isoleucine) and aromatic amino acids (such as tryptophan and tyrosine).
Mammalian target of rapamycin (mTOR).
A conserved serine/threonine protein kinase that can regulate cell growth and metabolism in response to environmental cues. mTOR receives stimulatory signals from RAs and phosphoinositide 3-kinase (PI3K) downstream of growth factors and nutrients, such as amino acids, glucose and oxygen.
Oxidative phosphorylation
A metabolic process that encompasses two sets of reactions that occur in the mitochondria. The first reaction involves the conversion of intermediate molecules (pyruvate and fatty acids) to acetyl coenzyme A (acetyl-CoA) and the degradation of acetyl-CoA to carbon dioxide in the tricarboxylic-acid cycle, yielding 'free' electrons that are carried by NADH and fADH 2 . The second reaction involves the transfer of electrons from NADH and fADH 2 to the electron-transport chain, resulting in the movement of protons out of the mitochondrial matrix. The resulting electrochemical potential is used by the f 1 f 0 ATP synthase to synthesize ATP.
Perforin
A component of cytolytic granules that participates in the permeabilization of plasma membranes, allowing granzymes and other cytotoxic components to enter target cells.
Rapamycin
An immunosuppressive drug that blocks mTOR.
Rate-limiting glycolytic enzymes
The enzymes hexokinase, phosphofructokinase and pyruvate kinase, which catalyse the three enzymatic steps in the glycolytic pathway that are essentially irreversible. Allosteric, transcriptional and post-translational regulation of these enzymes is crucial for the regulation of glycolysis. Phosphofructokinase catalyses the main rate-limiting step of glycolysis and is the most important control point.
Transferrin receptor
(Also known as CD71). A receptor that regulates the cellular import of iron by binding the iron-carrier protein transferrin.
Control of CD8 + T cell migration AKT and migration. Recent work has established that the activation of AKT downregulates the expression of the adhesion molecule CD62L (also known as L-selectin) and the chemokine receptors CC-chemokine receptor 7 (CCR7) and sphingosine-1-phosphate receptor 1 (S1P 1 ; also known as S1PR1) in CD8 + T cells; through this mechanism AKT determines the different trafficking patterns of naive and effector T cells 18, 19, 53 . naive and memory CD8 + T cells constantly circulate between the blood, lymphoid tissues and lymphatic vessels. By contrast, activated CD8 + T cells must suspend migration and reside in lymphoid tissue while they clonally expand and differentiate into effector CTLs. It is then vital that effector CTLs regain their motility, exit the lymphoid tissue and migrate to the site of infection to mount an immune response. The balanced and differential trafficking of naive versus effector CD8 + T cells is thus crucial for the function of CD8 + T cells during adaptive immune responses.
In this context, naive and memory CD8 + T cells enter secondary lymphoid organs because they express CCR7 and can react to a gradient of CCR7 ligands that allows them to cross the endothelial cell barrier in specialized high endothelial venules (HEvs) 17, 54 . naive and memory CD8 + T cells also express high levels of CD62L, which mediates the first step of transendothelial migration -the capture and rolling of T cells on the endothelium of HEvs. Once T cells are in the lymph nodes their migration is coordinated by the fibroblastic reticular cell (FRC) network, chemokines such as CCR7 ligands (CCL19 and CCL21), and sphingosine-1-phosphate (S1P) 54, 55 . naive T cells then spend several hours in the lymph node before exiting into the efferent lymphatic vessels and returning to the circulation. The egress of T cells from lymph nodes is determined by S1P 1 (Refs 55,56) . Activated T cells are retained in the lymph node because they downregulate or inactivate the expression of S1P 1 (Refs 55-57). They then undergo a period of clonal expansion and differentiation to effector CTLs, at which point the cells regain S1P 1 function and exit to the periphery. Effector CTLs migrate to sites of inflammation or infection, and have a reduced ability to home to peripheral lymph nodes compared with naive and memory CD8 + T cells. The changes in the trafficking behaviour of effector CTLs occur because the cells downregulate CCR7, CD62L and S1P 1 expression and upregulate the expression of pro-inflammatory adhesion molecules (such as vLA4 (very late antigen 4) and ligands for P-selectin and E-selectin) and proinflammatory chemokine receptors (such as CXC-chemokine receptor 3 (CXCR3) and CCR5) 54, 57, 58 . The loss of CD62L, CCR7 and S1P 1 expression by CTLs is an important mechanism that prevents these effector CTLs from re-entering secondary lymphoid organs and allows their redirection to peripheral tissues. Moreover, the importance of tightly regulating the expression of these receptors is evidenced by observations that changes in the turnover of S1P 1 , CCR7 or CD62L can markedly modify CTL-mediated immune responses 58, 59 . Recently, some of the molecular mechanisms that control the expression of these key receptors have been described. One of the first clues came from observations that the cytokines IL-2 and IL-15 differed in their ability to downregulate CD62L expression on antigen-primed CD8 + T cells and diffferentially regulated AKT activation 16, 17 . Antigen-primed CD8 + T cells that are cultured in the presence of IL-2 sustain AKT activation at high levels and downregulate CD62L. By contrast, T cells that are cultured with IL-15 sustain only low-level AKT activation and fail to downregulate CD62L expression 16, 17 . These observations were initially speculative but subsequent work verified that CD62L, CCR7 and S1P 1 expression by CD8 + T cells reflected the level of AKT activation in the cell [17] [18] [19] ( fIG. 2) . Hence, effector CTLs have high levels of AKT activity, express low levels of CD62L, CCR7 and S1P 1 and cannot traffic from the blood to lymphoid tissue. By contrast, CTLs that cannot fully activate AKT retain expression of CD62L, CCR7 and S1P 1 and retain the ability to traffic to lymph nodes 18 . Conversely, in naive T cells, which normally express high levels of CD62L, CCR7 and S1P 1 , PDK1-mediated activation of AKT is sufficient to terminate the expression of these homing receptors and prevent the cells from homing to peripheral lymph nodes or spleen 19 . Therefore, lymph node homing by T cells is controlled by the level of AKT signalling, which controls the expression of key adhesion and chemokine receptors that direct T cells into the secondary lymphoid tissues.
FOXO, mTOR and T cell migration.
How does active AKT suppress the expression of CD62L? The answer to this question lies in the ability of AKT to control the activity of the forkhead box O (FOXO) family transcription factors FOXO1 and FOXO3A, and hence to control the expression of the transcription factor Krüppel-like factor 2 (KLF2) 53 Another way in which AKT could control the expression of KLF2 is by regulating mTOR in the mTORC1 complex 65 . AKT phosphorylates and inactivates the RHEB GTPase-activating protein tuberin (TSC2), resulting in the accumulation of RHEB-GTP, which activates mTORC1 (fIG. 3) . AKT also regulates mTORC1 by phosphorylating PRAS40 (40kDa proline-rich AKT1 substrate, also known as AKT1S1), thereby blocking PRAS40-mediated inhibition of mTORC1 (Ref. 66) (fIG. 3) . The mTORC1 complex can regulate protein synthesis by controlling ribosomal biogenesis and the translation of a subset of mRnAs 65, 67 , although it is not known whether these metabolic functions of mTOR are important in T cells. However, mTOR activation does downregulate the expression of KLF2 and, therefore, CD62L, CCR7 and S1P 1 (Ref. 17) . The molecular details of the control of KLF2 expression by mTOR in T cells remains to be fully determined but it seems to be independent of regulated FOXO phosphorylation or localization (D.F. and D.A.C., unpublished observations).
The salient fact about the link between mTORC1 and KLF2 is that the mTORC1 inhibitor rapamycin, which is widely used clinically as an immunosuppressant, causes CTLs to re-express KLF2, CD62L and CCR7 and regain the ability to home to lymph nodes 17 . It is generally believed that rapamycin suppresses immune responses through its suppression of T cell proliferation. However, it is now clear that rapamycin treatment can also redirect the trafficking of effector CTLs from peripheral tissues to the lymph nodes and spleen 17 . The ability to redirect CTLs to secondary lymphoid tissue would result in their retention in secondary lymphoid organs and hence prevent immune destruction of target cells in peripheral tissues. It could also promote the destruction of antigen-primed antigen-presenting cells (APCs) by CTLs in lymph nodes, which could contribute to the clinical efficacy of rapamycin as an immunosuppressant.
Determining metabolism versus migration Different AKT activation thresholds. The discussions above indicate how AKT can control the activity of pathways that converge to control T cell migration (fIG. 4) . However, one significant observation is that AKT does not function as a simple on/off switch in T cells; rather, the magnitude of AKT activity is relevant. This insight comes from studies of T cells homozygous for a knock-in mutant of PDK1 (Lys465Glu) that cannot bind PtdIns(3,4,5)P 3 (Refs 18, 22) . The integrity of the PDK1 PH domain is not required for PDK1 catalytic activity but the loss of PtdIns(3,4,5)P 3 -binding by PDK1 strongly reduces AKT phosphorylation and activation. The PDK1 Lys465Glu mutant can thus only support submaximal activation of AKT in activated T cells (approximately 10-20% of that in wild-type T cells) 18 . Intriguingly, the low levels of AKT activity in T cells expressing the PDK1 Lys465Glu mutant are sufficient for T cell growth and proliferation, and thus are clearly sufficient to support T cell metabolism during thymopoiesis and during the T cell response to cognate antigen. However, these low levels of AKT activity are not sufficient to terminate the expression of KLF2 or to switch the chemokine and adhesion receptor profile of naive T cells to that of CTLs.
These data suggest that the initial strength of TCR triggering might dictate the outcome of an immune response by controlling the ability of the T cells to migrate rather than by controlling their ability to proliferate. For example, the downregulation of S1P 1 following CD8 + T cell activation is one of the mechanisms that retain activated CD8 + T cells in lymph nodes, but only occurs if there is strong activation of AKT. Activation with weak TCR agonists that cause weak activation of AKT might thus support T cell proliferation but would be unable to downregulate S1P 1 expression and, therefore, the T cells would not be retained in the lymph nodes. The premature exit of activated CD8 + T cells from lymph nodes into the blood in response to weak stimulation has been observed 68 , and would curtail CD8 + T cell exposure to APCs and pro-inflammatory cytokines, resulting in an attenuated immune response.
AMPK, mTOR and T cell memory.
It has recently been proposed that changes in T cell metabolism might be at the core of the decision of CD8 + T cells to produce memory T cells rather than terminally differentiated effector T cells [69] [70] [71] . This idea originates from experiments showing that treatment of mice with the mTOR inhibitor rapamycin increases the production of memory CD8 + T cells by accelerating the conversion of effector CD8 + T cells into the memory pool 69, 71 . It has also been shown that the activation of AMPK in mice by treatment with the drug metformin enhances the production of memory Mammalian target of rapamycin (mTOR) activity is regulated by the balance of multiple signalling pathways. Phosphoinositide 3-kinase (Pi3K)-AKT signalling activates mTOR complex 1 (mTORC1) through the phosphorylation of the GTPaseactivating protein (GAP) tuberin (TsC2) at position ser1462. This phosphorylation event results in the dissociation of the hamartin (TsC1)-TsC2 complex and thus prevents TsC2 from stimulating the intrinsic GTPase activity of the small G protein RHeB, resulting in the accumulation of GTP-bound RHeB, which is a positive regulator of mTORC1. AKT also phosphorylates 40 kDa proline-rich AKT1 substrate (PRAs40; also known as AKT1s1) at position Thr246, resulting in its dissociation from mTOR and thus blocking PRAs40-mediated mTORC1 inhibition. AMPactivated protein kinase (AMPK) activity inhibits mTORC1 by phosphorylating both TsC2 and the mTORC1 component regulatory associated protein of mTOR (RAPTOR). Phosphorylation of TsC2 (at Thr1227 and ser1345) by AMPK positively regulates its GAP activity, leading to RHeBmediated GTP hydrolysis, thereby preventing activation of mTORC1. Phosphorylation of RAPTOR (at ser722 and ser792) facilitates its binding to 14-3-3 proteins (not shown) and the subsequent inhibition of mTORC1 function. 71 . These two sets of observations might be linked because metformin interferes with oxidative phosphorylationmediated ATP synthesis through inhibition of respiratory chain complex I, and hence causes an increase in cellular AMP/ ATP ratio. This energy stress can drive an LKB1-dependent activation of AMPK, which then phosphorylates TSC2 and RAPTOR (regulatory associated protein of mTOR) to coordinately suppress mTORC1 activity 72 (fIG. 3) .
The T cell memory experiments with metformin were initiated by the observation that TnFR-associated factor 6 (TRAF6)-deficient CD8 + T cells cannot develop into memory CD8 + T cells and have reduced activity of AMPK 71 . However, whether AMPK-deficient T cells can develop into memory T cells has not been directly assessed. Moreover, evidence is emerging that metformin can control cellular metabolism independently of AMPK 73, 74 . nevertheless, as the primary effect of metformin is to inhibit respiratory chain complex I 74 , the metformin data are a good indication that changes in cell metabolism can change T cell behaviour.
However, there are many issues to resolve concerning the effect of metformin on T cell memory. First, there has been no clear demonstration that the in vivo effects of metformin reflect the action of this drug specifically on T cells rather than on other cells of the immune system. Second, it needs to be proved that metformin acts through AMPK. One other factor to be considered is that mTOR and AMPK should not be considered solely as enzymes that control T cell metabolism. For example, the ability of mTOR to control T cell migration by regulating the expression of KLF2, CD62L, CCR7 and S1P 1 is independent of any metabolic function of this enzyme 17 . Rapamycin treatment restores expression of KLF2 and its targets in IL-2-maintained CTLs and redirects CTL trafficking to secondary lymphoid tissue, even though IL-2-mediated control of CD8 + T cell survival and proliferation is not rapamycin sensitive 17 . How could inhibition of mTORC1 with rapamycin or through activation of AMPK promote the transition of effector CTLs to memory CD8 + T cells? One explanation could be the ability of rapamycin to reprogramme the trafficking of effector CTLs such that these cells regain the ability to enter secondary lymphoid tissue 17, 75 . This would bring them into the proximity of stromal cells, which produce cytokines (such as IL-7 and IL-15) that are required for the survival and homeostasis of memory T cells. It is also relevant here that in CD8 + T cells, mTOR activation is required to sustain the expression of the transcription factor T-bet while suppressing the expression of eomesodermin 75 (fIG. 4) . The molecular basis for mTOR-mediated control of T-bet and eomesodermin expression is not known nor is it clear if this is in any way linked to the role of mTOR as a metabolic regulator. However, the balance of T-bet and eomesodermin expression can determine the effector or memory fate of CD8 + T cells 76 , and the ability of mTOR to control the expression of these transcription factors gives some insights into how levels of mTOR activity might determine CTL fate.
T-bet is a key transcription factor in CTLs and is important for driving expression of the cytolytic differentiation programme 58 . This raises the fundamental question of whether changes in CD8 + T cell metabolism determine the effector or memory fate of CD8 + T cells by directly controlling their differentiation. It is however intriguing that T-bet also controls the expression of P-selectin ligands and CXCR3, which are crucial for the trafficking of effector CD8 + T cells to sites of inflammation 58, 77 . Thus an alternative view is that enzymes that evolved to control T cell metabolism have gained the ability to control T cell migration, and that it is their effects on migration and T cell homing that influence the fate of CD8 + T cells. This view is probably too simplistic, but if T cells migrate to different sites, they will have the potential to adopt different fates because they will exist in a different cytokine and chemokine milieu. The most probable scenario is that mTOR controls CD8 + T cell fate by a combination of mechanisms, including regulating T cell trafficking and directing the expression of the key transcription factors that control CTL effector function.
What about the proposal that metabolism regulates T cell memory? This concept stems from the recognition that mTOR can control immunological memory and the underlying dogma that mTOR controls T cell metabolism. However, there is no direct evidence that mTOR regulates T cell metabolism in the cellular models that demonstrate a role for mTOR in CTL function. nevertheless, it should be remembered that mTOR activity will be determined by nutrient availability 78 . Hence any change in the strength or quality of T cell activation during an immune response could cause suboptimal expression of nutrient receptors on T cells, thereby limiting their glucose and amino acid uptake and limiting the strength of mTOR activation. + T cell migration by regulating the expression of Krüppel-like factor 2 (KLF2), which controls the expression of chemokine receptors and adhesion molecules that are crucial for lymph node homing. mTORC1 also regulates the expression of T-bet, which induces the expression of P-selectin ligands and CXC-chemokine receptor 3 (CXCR3), both of which are crucial for the trafficking of effector CD8 + T cells to sites of inflammation. in addition, mTORC1 regulates the balance of T-bet and eomesodermin; these transcription factors are known regulators of effector versus memory CD8 + T cell function. T-bet is required for the cytotoxic functions of effector T cells and the production of effector cytokines, whereas eomesodermin expression is required for the acquisition of the memory phenotype. AMPK, AMP-activated protein kinase; CCR7, CC-chemokine receptor 7; FOXO, forkhead box O; iL-7R, interleukin-7 receptor; s1P 1 , sphingosine-1-phosphate receptor 1.
Differential AKT and mTOR signalling
There is a lot of evidence that effector and memory T cells can develop from a common naive T cell progenitor [79] [80] [81] One plausible idea is that competition for essential cytokines, such as IL-2, IL-12 and IL-15, could be the mechanism that creates heterogeneity in mTOR signalling in T cells. It is quite reasonable to assume that levels of these cytokines are finite in any tissue. It is also well established that sustained signalling by these cytokines is essential for CD8 + T cell differentiation. Moreover, in the context of IL-2 signal transduction, the 'strength' and duration of exposure to IL-2 is important 83, 84 . In vivo studies show that CD8 + T cells that express high levels of the high-affinity IL-2 receptor are more likely to develop into terminally differentiated effector CD8 + T cells, whereas cells with lower levels of IL-2 receptors give rise to longlived memory CD8 + T cells 84 . Similarly, in vitro experiments show that antigenprimed CD8 + T cells that are cultured with high-dose IL-2 differentiate into effector CTLs, whereas cells that are cultured in low-dose IL-2 differentiate into memory CD8 + T cells 83 . Importantly, IL-15 could only support the production of memory CD8 + T cells, reflecting the fact that IL-15 can only weakly activate AKT in antigen-primed CD8 + T cells 16, 17, 83 . So a simple idea of how a single antigenprimed naive CD8 + T cell could produce progeny that are heterogeneous for AKT activation is to consider that populations of T cells have to compete for cytokines such as IL-2 (fIG. 5) . This could be a stochastic process initially or it could be directed by heterogeneity in the expression of the IL-2 receptor by CTLs 84 . Cells with a low level of IL-2 signalling would have lower levels of AKT and mTOR activity. As discussed, this would change the trafficking properties of these cells and any heterogeneity would be reinforced when the cells moved to different microenvironments. It is also relevant that IL-2 is a potent regulator of the expression of the receptors for key cytokines that determine CD8 + T cell fate: IL-2 can thus positively regulate IL-12 receptor expression 85 and negatively control IL-7 receptor levels 86 . Therefore, in addition to altering T cell migratory properties as a result of lower AKT and mTOR activity, low-dose IL-2 would cause CD8 + T cells to downregulate IL-12 receptor expression and increase their expression of IL-7 receptors. This would favour their differentiation towards a memory CD8 + T cell fate. Returning to the theme of metabolism, high levels of IL-2 signalling could support the high metabolic rate required for effector CTL responses, whereas low levels of IL-2 would not. ) circulate between the blood, lymph nodes and efferent lymphatics. These T cells express several molecules that are crucial to this trafficking cycle. CD62L (also known as L-selectin) mediates adhesion to high endothelial venules (Hevs), CC-chemokine receptor 7 (CCR7) directs transendothelial migration into lymph nodes, and sphingosine-1-phosphate receptor 1 (s1P 1 ) directs T cell migration into the efferent lymphatic vessels. b | During an infection, CD8 + T cells are activated by their cognate antigen when it is presented to them by antigen-presenting cells in the lymph node. They then cease trafficking, and proliferate and differentiate to produce effector cytotoxic T lymphocytes (CTLs; T e ). After a period, the CTLs exit the lymph node, and strongly activated cells that no longer express CD62L or CCR7 are unable to re-enter secondary lymphoid tissue. Moreover, such strongly activated CTLs will upregulate the expression of P-selectin and e-selectin ligands and pro-inflammatory chemokine receptors such as CXC-chemokine receptor 3 (CXCR3), allowing them to traffic across inflamed endothelium to sites of infection and inflammation. As the infection resolves, cytokines become limiting at the site of inflammation, and in the absence of these survival signals effector CTLs undergo apoptosis (not shown). The loss of cytokine signalling also causes loss of AKT-mammalian target of rapamycin (mTOR) signalling and could allow re-expression of CD62L and CCR7 on some CTLs and hence allow these cells to return to secondary lymphoid tissues. This would bring them into proximity with the stromal cells that produce the homeostatic cytokines iL-7 and iL-15. in this environment, these T cells have the potential to generate memory CD8 + T cells (T M ). An alternative possibility is that cells that only weakly activate AKT-mTOR signalling during the initial immune activation within the lymph nodes could retain the expression of CD62L and CCR7, and hence immediately resume a pattern of homing to secondary lymphoid organs, which would favour their development into memory T cells. P e r s P e c t i v e s nATuRE REvIEWS | Immunology vOLuME 11 | FEBRuARy 2011 | 115
f o c u s o n m e ta b o l i s m a n d i m m u n o lo g y This is obviously an over-simplistic view and it is unlikely that the complexities of effector versus memory CD8 + T cell decisions can be explained on the basis of how T cells deal with a single cytokine. However, these cell fate decisions could be explained by a model that places AKT and mTOR at the core of a pathway that integrates signals from a wide range of cytokines, co-stimulatory molecules and antigen receptors to direct CD8 + T cell fate. The key to this model is that the strength and duration of AKT, and hence mTOR, activation is determined by the balance of signals from these surface receptors, so there are multiple routes to modulate AKT activation at any time as T cells respond to immune-mediated activation signals.
In addition to the example of cytokine competition discussed above, another route could involve changes in the levels of TCR triggering. Effector CD8 + T cells at the sites of infection might sustain high levels of AKT activity as a result of continual antigen receptor occupancy. Then, as pathogens are cleared from the body, the levels of TCR triggering would decrease, allowing the levels of active AKT to drop and thereby directing the CD8 + T cells to home back to secondary lymphoid tissues where competition for homeostatic cytokines would determine the number of memory CD8 + T cells that could be supported within a particular niche.
Concluding remarks
We still have much to learn about how CD8 + T cells control their metabolism to meet the energy demands of their effector function. However, we have begun to understand an extraordinary amount about how the enzymes that evolved to control T cell metabolism are also able to control T cell migration and differentiation and determine the balance of effector versus memory CD8 + T cell development. We have also been able to see how changes in the strength of activation of serine/threonine kinases can create hetero geneity in signal transduction pathways, allowing a single T cell to generate progeny that have different fates. This work provides important insights about pharmacological strategies that might be able to manipulate immune responses to ensure effective vaccination and/or stem the T cell pathology caused by effector CTLs.
